# Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

> **NCT07028970** · — · RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 1500 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )

## Key facts

- **NCT ID:** NCT07028970
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2040-12
- **Final completion:** 2043-12
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028970, "Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07028970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*